<DOC>
	<DOCNO>NCT01706965</DOCNO>
	<brief_summary>Rater blind trial six week Kuvan vs. multivitamin 60 outpatient schizophrenia schizoaffective disorder . The aims evaluate anticipate clinical response Kuvan treatment include negative symptom cognitive deficit , evaluate safety Kuvan treatment schizophrenic patient evaluate relationship change plasma Kuvan level efficacy outcomes .</brief_summary>
	<brief_title>Kuvan People With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description>Tetrahydrobiopterin ( BH4 ) vital central nervous system ( CNS ) cofactor maintain availability amine neurotransmitter dopamine ( DA ) serotonin ( 5HT ) , stimulate modulates glutamatergic system . Dysregulation neurotransmitter system implicate pathogenesis schizophrenia ( SZ ) . A central role BH4 schizophrenia support study find relative deficit 32 % SZ patient compare control . The observed BH4 deficit comparable report genetic BH4 deficiency disorder , support characterization physiological significance . This highly significant finding , along : ) know role BH4 neurotransmitter maintenance , b ) dysregulation CNS neurotransmitter synthesis observe human BH4 deficiency , c ) evidence plasma biopterin level correlate CNS biopterin level , ) evidence urinary biopterin excretion increase SZ , support hypothesis dysregulation BH4 biosynthesis involve pathophysiology SZ . Moreover , additional data suggest mood stabilizer drug moderately increase level biopterin patient psychiatric disorder , report efficacy BH4 pilot study neuropsychiatric disorder , suggest alleviation schizophrenia BH4 deficit via treatment synthetic BH4 supplement ( Sapropterin dihydrochloride Kuvan ) , may give rise improvement symptom schizophrenia , include positive negative symptom well neurocognitive deficit . Sapropterin dihydrochlorides , teh active pharmaceutical ingredient Kuvan Tablets , synthetic preparation dihydrochloride salt naturally occur tetrahydrobiopterin ( BH4 )</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Male female outpatient schizophrenia schizoaffective disorder Ages 1864 A score 45 great PANSS All oral depot antipsychotic ( exception clozapine ) allowable . Patients must antipsychotic medication 3 month stable dose antipsychotic adjunctive medication 2 week prior study entry . If patient depot medication , must stable dose 2 month Organic brain disorder , include epilepsy ; mental retardation ; medical condition whose pathology treatment would likely alter presentation treatment schizophrenia Participated investigational study take investigational drug within 30 day Current Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) diagnosis drug/alcohol abuse last month current DSMIV diagnosis drug/alcohol dependence last 6 month . Subjects must negative drug screen baseline ( one retest allow suspect false positive base clinical judgement investigator ) Diagnosis know BH4 deficiency disorder ( schizophrenia schizoaffective disorder ) , include doparesponsive dystonia , phenylketonuria ( PKU ) , autism Current treatment clozapine In investigator 's judgment , significant risk suicide violent behavior Current use levodopa nitric oxidemediated vasorelaxation oral minoxidil Women exclude pregnant , lactating , either surgicallysterile use appropriate method birth control . Women must agree continue use applicable birth control throughout trial . All woman childbearing potential must negative urine pregnancy test screen visit visit 2 ( 1 week begin study medication ) Absolute neutrophil count 2.0 screen Any contraindication allergic reaction previous multivitamin unwillingness stop use current multivitamin study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>